The new antiepileptic drug perampanel;Das neue antiepileptikum perampanel: Eine aktuelle übersicht

Psychopharmakotherapie

Volumn 19, Issue 5, 2012, Pages 202-208

  Steinhoff, Bernhard J ^a  

^a EPILEPSIEZENTRUM KORK   (Germany)

Author keywords

Antiepileptic drug treatment; Epilepsy; Glutamate; Perampanel

Indexed keywords

AMPA RECEPTOR; PERAMPANEL;

DRUG APPROVAL; EUROPE; FOCAL EPILEPSY; GOLD STANDARD; HUMAN; LICENCE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84867194472     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Bialer M, Johannessen SI, Levy RH, Perucca E, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89-124.
2. Chappell AS, Sander JW, Brodie MJ, Chadwick D, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-2. (Pubitemid 34602903)
3. French J, Krauss GL, Biton V, Squillacote D, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96.
4. French JA, Krauss GL, Steinhoff BJ, Squillacote D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia 2012. Im Druck, doi: 10.1111/j.1528-1167.2012.03638.x. (Epub ahead of print).
5. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40.
6. Krauss GL, Bar M, Biton V, Klapper JA, et al. Tolerability and safety of permapanel: two randomized dose-escalation trials. Acta Neurol Scand 2012;125:8-15.
7. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, et al. Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III extension study 307. Epilepsia. Im Druck, doi: 10.1111/j.1528-1167.2012.03648.x. (Epub ahead of print).
8. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15.
9. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug treatment. Neurotherapeutics 2007;4:18-61. (Pubitemid 46107329)
10. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63.
11. Steinhoff BJ. Pharmakotherapie der Epilepsie. Klin Neurophys 2012;43:131-7.
12. Steinhoff BJ, Herrendorf G, Bittermann H-J, Kurth C. Neue Antiepileptika: Gabapentin. Epilepsie-Blätter 1995;8:3-11.
13. Vollmar W, Gloger J, Berger E. RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol Dis 2004;15:371-9. (Pubitemid 38296768)
14. Zules K, Qu MS, Köhling R, Speckmann EJ. Ionotropic glutamate and GABA receptors in human epileptic tissue: quantitative in vitro receptor autoradiography. Neuroscience 1999;94:1051-61. (Pubitemid 29509672)